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Introduction to ERK 1/2 Proteins

Aim 1 Goals and Methods

ERK 1 and ERK 2 are protein kinases that regulate both cell regulation
and cellular proliferation. Activation of these proteins occurs through
phosphorylation within the proteins. Once activated these proteins initiate
anti-apoptosis processes increasing the chance of cell survival. Research
has demonstrated that increased ERK 1/2 activity lowers the development
of high-fat diet induced obesity. (Figure 1). In a similar study ERK 1/2
was also found to decrease heart failure and cardiac pathologies.
Specifically this study demonstrated that cardiac contractility and faster
relaxation times were evident in those mouse models with elevated ERK
1/2 levels.1

Streptozotocin is widely used drug to induce diabetes in small animals.
Streptozotocin kills the beta cells within the pancreas, which are the main
source of insulin in the body. The drug accomplishes this killing via
interruption of DNA structure through alkylation as well as through the
creation of toxic chemicals such as hydrogen peroxide and nitric acid.
The first aim of this study will be to induce diabetes in both wild type
and DUSP 6/8 knockout mice. (These mice are from strains that have
already been genetically altered to remove DUSP6/8 genes, see Figure 2).1
This will be done by injecting the mice with Streptozotocin five days
consecutively through via intraperitoneal injection techniques. Glucose
levels will be monitored before injection and two weeks after injection to
determine if diabetes is induced in the mice.6-8

Overview of Diabetic Cardiomyopathy
Diabetic cardiomyopathy is a subset of heart disease that is characterized
by mitochondrial dysfunction, hypertension and an overall inability of the
heart to pump adequately. The causation behind the correlation between
the increased rate of development of cardiomyopathy in those individuals
afflicted with diabetes is unknown, but abnormal cardiac fuel usage and
intracellular lipid accumulation have been suggested. In a diabetic body
there is a surplus of fatty acids in the blood as it is used as compensation
for the body´s inability to use glucose as fuel, due to the inadequate or
complete lack of insulin. This surplus of fatty acid can travel to the heart
causing buildups which may lead to cardiomyopathy. These reasons are
still being investigated to determine if these diseases are linked
physiologically or are caused by similar environmental factors.4-5

Aim 2 Goals and Methods
The main goal of this study is to determine if DUPS 6/8 knockout mice
are protected from diabetic cardiomyopathy. Following the process of
Streptozotocin injection described in aim 1 those mice who develop
diabetes (determined through the measurement of glucose levels) will be
chosen to assess cardiac function 12 weeks following injection.
To assess cardiac function Brain Natriuretic Peptide, Troponin and
mitochondrial saturation levels will be determined. Brain Natriuretic
Peptide levels are increased significantly during heart failure. High cardiac
output which is often associated with cardiomyopathy causes for an
increase in Brain Natriuretic Peptide and is a reliable method of
determining heart failure.2 Troponin is a protein found in cardiac and
skeletal muscle and is vital for contraction control. When the heart muscle
is injured Troponin is released in the blood and can be directly measured as
an indicator of cardiomyopathy.2 Finally, mitochondria are vital to ATP
creation within the cell that allow for effective contraction. Mitochondrial
dysfunction has been shown to be directly related to cardiomyopathy as the
heart is no longer able to properly function when ATP is depleted. In order
to test the activity of mitochondria within the heart oxygen consumption
rates can be measured as the mitochondria generates ATP using aerobic
respiration. Measuring the exact saturation of mitochondria can also be
measured using biomarkers as identifiers.3

Apoptosis in Diabetic Cardiomyopathy
Another factor that has been suggested as a correlation to the
development of heart failure is an increased level of apoptosis within
myocardial cells. Caspase-3 is an enzyme vital in the apoptosis pathway.
In prior studies levels of Caspase-3 in mice induced with diabetic
cardiomyopathy were investigated to determine any relationship between
cardiomyopathy and apoptosis levels. A positive correlation was found
demonstrating that apoptosis pathways are indeed elevated in cases of
diabetic cardiomyopathy.3
Within the same study mitochondrial concentrations were measured
within the myocardial tissue. It was found that mitochondrial
concentrations were decreased in the tissues with elevated levels of
Caspase-3. Specifically the mice induced with diabetic cardiomyopathy
via Streptozotocin, demonstrated low levels of mitochondrial saturation.
(See figure 3).3
This finding further solidifies prior findings that suggest that
mitochondrial depletion is an indicator in the development of
cardiomyopathy.
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